NCT05312567: FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms |
|
|
| Completed | 2 | 105 | US | FP-101 | Fervent Pharmaceuticals, ICON plc | Vasomotor Symptoms, Menopause | 04/23 | 07/23 | | |
| Active, not recruiting | 2 | 1380 | US | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |